The life sciences industries are a crucial partner in efforts to curb AMR. Within this context, the AMR Industry Alliance (AMRIA) was established in 2017 and brings together leading biopharmaceutical, biotechnology, diagnostic, generics companies and industry associations to address AMR-related issues.

The principles of the AMR Industry Alliance are based on its two founding documents: the Davos Declaration and the Industry Roadmap. Since then, Alliance commitments have evolved in line with industry progress and global priorities.

The Alliance measures and drives the life-sciences industry progress to curb antimicrobial resistance in four different areas: research and science, appropriate use, access, manufacturing.

RESEARCH & SCIENCE 

• Invest in research and development for innovative antibiotics and antibiotic dosage forms, vaccines, new technologies, and diagnostics.
• Continue to advocate for policies that support sustainable investment in AMR-relevant innovation.
• Partner with policymakers, payers, and other relevant stakeholders on new reimbursement, valuation, and commercial models that support appropriate patient access and a sustainable supply of antibiotics and AMR-relevant vaccines and new technologies and diagnostics.
• Support collaboration and sharing of relevant non-proprietary data with different stakeholders (e.g., academia, consortia, small or medium-sized enterprise (SMEs), public researchers and industry) to help address key scientific and public health challenges.

ACCESS 

• Address barriers to patient access to the most appropriate treatment, vaccine, or diagnostic.
• Work in collaboration with policymakers to create an economic and regulatory environment that enables the sustainable supply of quality-assured antibiotics.
• Work to reduce the prevalence of substandard and falsified AMR-relevant products.

APPROPRIATE USE 

• Contribute to slowing the emergence of resistance by preventing infections by promoting vaccination and reduction of inappropriate use of antibiotics through expanded use of diagnostics.
• Support appropriate use of antibiotics by working closely with other partners on awareness campaigns, continued education for healthcare professionals, and generation of evidence to support appropriate use and stewardships.
• Collect and share surveillance data with public health bodies and healthcare professionals to improve understanding of resistance trends, monitor the effectiveness of antibiotics, inform appropriate antibiotic and vaccine use, and develop adapted infection control strategies.
• Ensure that any promotional activities for antibiotics are aligned with the goal of advancing stewardship.

MANUFACTURING AND ENVIRONMENT 

• Review Alliance member’s own manufacturing and supply chains to assess good practice in controlling release of antibiotics into the environment.
• Establish a common framework for managing antibiotic discharge, and start to apply it across their own manufacturing and supply chains by 2018.
• Work with stakeholders to develop a practical mechanism transparently show that Alliance member supply chains meet the frameworks standards.
• Work with independent technical experts to establish science-driven, risk-based targets for discharge concentrations of antibiotics and develop good practice methods to reduce environmental impacts of manufacturing discharges by 2020.